Adenosine
As of the edition of 20 October 2026, Adenosine is a small molecule: marketed, first approved in 1961 (ES); acts on ADORA1, ADORA2A and ADORA2B and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1993
- Kind
- Small molecule
- Brand name
- Adenocard
- First approved
- 1 May 1961 (ES)
- Approvals on record
- 6 in 4 regions
- Holder of the most recent approval
- Astellas; 4 holders in all
- Registered trials
- 54, 9 stopped early
- Disease areas
- Heart and blood vessels; Immune system; Lungs and airways; Nutrition and metabolism; Cancer; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Adenosine.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 19 | 11 | 2 | 1 |
| Phase 1 | 9 | 6 | 2 | 1 |
| Phase 2 | 11 | 5 | 0 | 3 |
| Phase 3 | 12 | 7 | 1 | 4 |
| Phase 4 | 3 | 2 | 1 | 0 |
| All trials | 54 |